** Brokerage Piper Sandler initiates coverage on drug developer Compass Therapeutics CMPX.O with an "overweight" rating and a PT of $12
** Brokerage says results from a mid-to-late stage trial, for co's lead drug, tovecimig, could potentially help boost shares
** Adds it will be a "win" if the drug shows more than 23% effect on improving overall response rate, which is the percentage of patients showing response to treatment
** Prior trial data for the drug when studied in combination with a type of chemotherapy paclitaxel in biliary tract cancer was promising
** This suggests its mid-to-late stage trial results (expected in March) should also report efficacy that will support regulatory approval - Piper Sandler
** Estimates peak US sales of $635 million if approved as a second line treatment for biliary tract cancer
** Co is also testing the drug in patients with colorectal cancer
** Stock has risen 71.3% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.